Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sequana Medical NV

< Previous 1 2 Next >
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
From Sequana Medical NV
Via GlobeNewswire
Press release: Transparency Notification from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares
From Sequana Medical NV
Via GlobeNewswire
Press release: Transparency Notification from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 22 May 2025
From Sequana Medical NV
Via GlobeNewswire
Press release: CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases
From Sequana Medical NV
Via GlobeNewswire
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical to Attend the “VFB Happening 2025” in Ghent, Belgium on Saturday, 29 March 2025
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
From Sequana Medical NV
Via GlobeNewswire
Press Release: Transparency Notification from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions
From Sequana Medical NV
Via GlobeNewswire
Press release: Transparency Notification from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Press release: Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
From Sequana Medical NV
Via GlobeNewswire
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
From Sequana Medical NV
Via GlobeNewswire
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
From Sequana Medical NV
Via GlobeNewswire
Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
From Sequana Medical NV
Via GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
From Sequana Medical NV
Via GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
From Sequana Medical NV
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.